title: Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity.
abstract: OBJECTIVE
  This study aimed to compare the efficacy of long-acting risperidone and zuclopenthixol in subjects with schizophrenia and substance abuse.
  
  
  METHODS
  A total of 115 subjects with schizophrenia and substance use disorders were enrolled for an open, randomized, controlled, 6-month follow-up study. Fifty-seven subjects were selected for treatment with long-acting injectable risperidone, while another 58 were treated with zuclopenthixol-depot.
  
  
  RESULTS
  Long-acting risperidone patients presented fewer positive urine tests (8.67 compared with 10.36, P = 0.005), showed improved scores on the Positive and Negative Syndrome Scale, and showed better compliance with the Substance Abuse Management program. The use of long-acting risperidone and less severe dependence explained the outcome at the end of the follow-up.
  
  
  CONCLUSIONS
  Long-acting injectable risperidone was more effective than zuclopenthixol-depot in improving substance abuse and schizophrenia symptoms in subjects with dual diagnosis.
authors.affiliation: Department of Psychiatry, Complutense University, Madrid, Spain. garuva@inicia.es
authors.forename: Gabriel
authors.initials: G
authors.lastname: Rubio
authors.forename: Isabel
authors.initials: I
authors.lastname: Martínez
authors.forename: Guillermo
authors.initials: G
authors.lastname: Ponce
authors.forename: Miguel Angel
authors.initials: MA
authors.lastname: Jiménez-Arriero
authors.forename: Francisco
authors.initials: F
authors.lastname: López-Muñoz
authors.forename: Cecilio
authors.initials: C
authors.lastname: Alamo
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003006:Clopenthixol / Q000627:therapeutic use*; D015897:Comorbidity; D003692:Delayed-Action Preparations / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D018967:Risperidone / Q000008:administration & dosage / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy* / Q000453:epidemiology*; D019966:Substance-Related Disorders / Q000453:epidemiology*
chemical_list: D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D003006:Clopenthixol; D018967:Risperidone